Longevity In Vitro Research Only

Humanin: Mitochondrial Neuroprotection, Longevity & Alzheimer’s Research

1,000× Greater Potency of S14G-Humanin vs. Native Form

Humanin (HN) is a 21-amino-acid peptide encoded in the mitochondrial 16S rRNA gene — a mitochondria-derived peptide (MDP) discovered in 2001 by Nishimoto et al. at the University of Tokyo while searching for genes protecting against Alzheimer's-associated neuronal death. IGF-1-deficient Laron syndrome patients, who exhibit exceptional longevity and reduced cancer/diabetes rates, have dramatically elevated humanin levels — providing human genetic evidence for humanin's role in healthy aging.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧠

Alzheimer's Neuronal Protection

Blocks pro-apoptotic activity of IGFBP-3, TIAL, and Alzheimer's-linked proteins (APP, presenilin mutations) — preventing neuronal death induced by amyloid-beta.

⚗️

STAT3 Anti-Apoptotic Signalling

Signals through a tripartite receptor complex (FPRL1) to activate STAT3, driving anti-apoptotic gene expression that protects multiple cell types from programmed death.

🔬

Insulin Sensitisation

Improves hepatic and peripheral insulin sensitivity, reduces gluconeogenesis, and suppresses TNF-α and IL-1β — acting as a systemic metabolic protector.

🧬

Reproductive Cell Protection

Protects testicular germ cells and oocytes from chemotherapy-induced damage — S14G-Humanin prevented cisplatin-induced oocyte death in mice, preserving ovarian reserve.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

🏛️

2001

Discovery Year

Nishimoto et al. University of Tokyo

🧬

mtDNA

Genomic Origin

Mitochondrial 16S rRNA gene

👴

Laron

Longevity Association

Elevated in exceptional lifespan patients

⚗️

1,000×

S14G Analogue Potency

vs. native humanin

Humanin Level Comparison Across Health States

Laron Syndrome (Longevity)

Age-Matched Controls

Alzheimer's Patients

Relative humanin serum levels (normalised %). Source: Muzumdar et al. (2009) Aging Cell. PMID 19843177.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

94%

Tolerability (Preclinical)

Low Severity

Limited Human Data

Medium Severity

Injection-Site Rxn

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.